Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by Hobberson Aug 09, 2014 10:00am
232 Views
Post# 22824943

RE:RE:RE:RE:With any luck...

RE:RE:RE:RE:With any luck...

This stock was at roughly 1.33 as recently as June and 1.25 in early July, just four or five weeks ago. BTI must have known then that they were going to need cash. Why didn't they finance back then? Did some sort of agreement for cash from a pharma unravel back then? Were there no other potential deals in sight?

 

Was the stock then walked down some 30 percent so that more shares and warrants would be available at a cheaper price to those allowed to buy them? It gives that appearance, at least to me, sad to say. That's a big, quick and possibly suspicious drop for a company that's supposed to be on the cutting edge in the bbb field.

 

I've apparently put too much faith in the science of this company while accusing my eyes of lying to me that the stock's tanking was signaling possiblr shenanigans.

 

I agree with oilpatch in questioning the need for so much cash if deals are imminent?

If they raise enough to last for a couple of years, my guess is that's what they're preparing for.

 

I'm half out and don't mind holding some dry powder. If the stock is going to 20 and more, I don't mind paying 5 or 6, as long as it's going in the right direction.

 

Bullboard Posts